Overview / Abstract: |
STATEMENT OF NEED Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases (ACS, 2020). TARGET AUDIENCE Oncologists, urologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with renal cell carcinoma (RCC). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1.) Assess recent clinical trial findings on first-line and second-line treatment of advanced RCC This activity is also available as a podcast. |
Expiration |
Nov 16, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Podcast, Webinar / Webcast / Video |
Credits / Hours |
0.5 CME/NCPD |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Bradley McGregor, MD (Chairperson) Robert Motzer, MD |
Activity Specialities / Related Topics |
Adverse Drug Reactions / ADR, Education / Teaching, Medication Safety, Nephrology, Oncology / Cancer / Radiation Therapy, Urology |
Sponsors / Supporters / Grant Providers |
This educational activity is supported by a medical education grant from Exelixis, Inc. and an independent educational grant from Merck. |
Keywords / Search Terms |
i3 Health oncology, urology, renal cell carcinoma, RCC, kidney cancer, genitourinary cancers, CME, CNE, NCPD, ILNA points, MOC, free CME, free CNE, free NCPD, free ILNA points, i3 Health Free CE CME |